$BRFH
BARFRESH FOOD GROUP INC. Stock $brfh

$brfh Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000149315223028441 Filed on August 14, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$2.603M	$1.511M	$2.799M
YoY Change	8.19%	-46.02%	115.14%
Cost Of Revenue	$1.690M	$1.037M	$1.916M
YoY Change	-45.99%	-45.88%	159.27%
Gross Profit	$913.0K	$474.0K	$883.0K
YoY Change	-226.28%	-46.32%	57.12%
Gross Profit Margin	35.07%	31.37%	31.55%
Selling, General & Admin	$1.275M	$1.118M	$1.503M
YoY Change	-31.93%	-25.62%	47.64%
% of Gross Profit	139.65%	235.86%	170.22%
Research & Development	$32.00K	$35.00K	$97.00K
YoY Change	-85.45%	-63.92%	-23.62%
% of Gross Profit	3.5%	7.38%	10.99%
Depreciation & Amortization	$102.0K	$87.00K	$110.0K
YoY Change	-2.86%	-20.91%	-15.38%
% of Gross Profit	11.17%	18.35%	12.46%
Operating Expenses	$1.389M	$1.216M	$1.620M
YoY Change	-30.03%	-24.94%	39.18%
Operating Profit	-$476.0K	-$742.0K	-$737.0K
YoY Change	-82.42%	0.68%	22.43%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$480.0K	-$742.0K	-$737.0K
YoY Change	-82.27%	0.68%	148.15%
Income Tax
% Of Pretax Income
Net Earnings	-$476.0K	-$742.0K	-$737.0K
YoY Change	-82.42%	0.68%	148.15%
Net Earnings / Revenue	-18.29%	-49.11%	-26.33%
Basic Earnings Per Share	-$0.04	-$0.06	-$0.06
Diluted Earnings Per Share	-$0.04	-$0.06	-$57.07K
COMMON SHARES
Basic Shares Outstanding	13.04M shares	13.00M shares	12.92M shares
Diluted Shares Outstanding	13.04M shares	13.00M shares	12.92M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.010M	$952.0K	$3.533M
YoY Change	-64.4%	-73.05%	-48.21%
Cash & Equivalents	$1.011M	$952.0K	$3.533M
Short-Term Investments
Other Short-Term Assets	$170.0K	$99.00K	$261.0K
YoY Change	-51.15%	-62.07%	38.06%
Inventory	$748.0K	$970.0K	$1.570M
Prepaid Expenses
Receivables	$1.159M	$362.0K	$1.245M
Other Receivables	$116.0K	$108.0K	$148.0K
Total Short-Term Assets	$3.201M	$2.491M	$6.757M
YoY Change	-36.06%	-63.13%	-21.32%
LONG-TERM ASSETS
Property, Plant & Equipment	$487.0K	$627.0K	$1.346M
YoY Change	-60.76%	-53.42%	-26.0%
Goodwill
YoY Change
Intangibles	$258.0K	$275.0K	$339.0K
YoY Change	-20.12%	-18.88%
Long-Term Investments
YoY Change
Other Assets	$10.00K	$7.000K	$7.000K
YoY Change	42.86%	0.0%	3.7%
Total Long-Term Assets	$752.0K	$909.0K	$1.745M
YoY Change	-53.2%	-47.91%	-21.59%
TOTAL ASSETS
Total Short-Term Assets	$3.201M	$2.491M	$6.757M
Total Long-Term Assets	$752.0K	$909.0K	$1.745M
Total Assets	$3.953M	$3.400M	$8.502M
YoY Change	-40.22%	-60.01%	-21.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.692M	$775.0K	$1.277M
YoY Change	-6.1%	-39.31%	99.15%
Accrued Expenses	$229.0K	$340.0K	$200.0K
YoY Change	-27.3%	70.0%	-74.58%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.660M	$1.937M	$1.761M
YoY Change	11.44%	9.99%	-4.41%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities			$0.00
YoY Change			-100.0%
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.660M	$1.937M	$1.761M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$2.660M	$1.937M	$1.761M
YoY Change	11.44%	9.99%	-28.29%
SHAREHOLDERS EQUITY
Retained Earnings	-$60.10M	-$59.62M	-$53.80M
YoY Change	6.36%	10.82%
Common Stock	$0.00	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.293M	$1.463M	$6.741M
YoY Change
Total Liabilities & Shareholders Equity	$3.953M	$3.400M	$8.502M
YoY Change	-40.22%	-60.01%	-21.37%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$476.0K	-$742.0K	-$737.0K
YoY Change	-82.42%	0.68%	148.15%
Depreciation, Depletion And Amortization	$102.0K	$87.00K	$110.0K
YoY Change	-2.86%	-20.91%	-15.38%
Cash From Operating Activities	$60.00K	-$825.0K	-$790.9K
YoY Change	-108.62%	4.32%	172.79%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$520.00
YoY Change		-100.0%	-101.57%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$0.00	$520.00
YoY Change		-100.0%	-101.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	0.000
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	60.00K	-825.0K	-790.9K
Cash From Investing Activities	0.000	0.000	520.0
Cash From Financing Activities	0.000	0.000	0.000
Net Change In Cash	60.00K	-825.0K	-790.3K
YoY Change	-108.62%	4.39%	-116.29%
FREE CASH FLOW
Cash From Operating Activities	$60.00K	-$825.0K	-$790.9K
Capital Expenditures	$0.00	$0.00	$520.00
Free Cash Flow	$60.00K	-$825.0K	-$791.4K
YoY Change	-108.62%	4.25%	208.14%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001487197
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
	BRFH	Value Of Shares Relinquished In Modification Of Stockbased Compensation Awards ValueOfSharesRelinquishedInModificationOfStockbasedCompensationAwards		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41228
	dei	Entity Registrant Name EntityRegistrantName	BARFRESH FOOD GROUP INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-1994406
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3600 Wilshire Blvd.
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1720
	dei	Entity Address City Or Town EntityAddressCityOrTown	Los Angeles
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90010
	dei	City Area Code CityAreaCode	310
	dei	Local Phone Number LocalPhoneNumber	598-7113
	dei	Entity Information Former Legal Or Registered Name EntityInformationFormerLegalOrRegisteredName	Not Applicable
	dei	Security12b Title Security12bTitle	Common stock, $0.000001 par value
	dei	Trading Symbol TradingSymbol	BRFH
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	13037948	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	952000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2808000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	211000	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	362000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	126000	usd
CY2023Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	108000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	101000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	970000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1048000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	99000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	79000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	2491000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	4373000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	627000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	801000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	18000	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	275000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	306000	usd
CY2023Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	7000	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	7000	usd
CY2023Q2	us-gaap	Assets Assets	3400000	usd
CY2022Q4	us-gaap	Assets Assets	5505000	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	775000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1534000	usd
CY2023Q2	us-gaap	Accounts Payable Underwriters Promoters And Employees Other Than Salaries And Wages Current AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent	499000	usd
CY2022Q4	us-gaap	Accounts Payable Underwriters Promoters And Employees Other Than Salaries And Wages Current AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent	499000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	340000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	286000	usd
CY2023Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	323000	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	233000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	20000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1937000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2572000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	1937000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2572000	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.000001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.000001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	400000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	400000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	23000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	23000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13002603	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13002603	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12934741	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12934741	shares
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	61082000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	60905000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-59619000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-57972000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	1463000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2933000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3400000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5505000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1511000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2799000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3602000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5325000	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	1037000	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	1916000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	2273000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	3678000	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	474000	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	883000	usd
	us-gaap	Gross Profit GrossProfit	1329000	usd
	us-gaap	Gross Profit GrossProfit	1647000	usd
CY2023Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	625000	usd
CY2022Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	701000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1293000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1376000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	493000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	802000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1487000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1624000	usd
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	98000	usd
CY2022Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	96000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	196000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	236000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	1216000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	1599000	usd
	us-gaap	Operating Expenses OperatingExpenses	2976000	usd
	us-gaap	Operating Expenses OperatingExpenses	3236000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-742000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-716000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1647000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1589000	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13003000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13003000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12915000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12915000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12990000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12990000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12915000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12915000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13003000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12915000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12990000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12915000	shares
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
	us-gaap	Net Income Loss NetIncomeLoss	-1647000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1589000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	205000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	244000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	118000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	93000	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	83000	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	98000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	236000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	22000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	7000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	148000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-78000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	865000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	22000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-11000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-759000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	303000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	120000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-48000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2067000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1923000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2067000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1931000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3019000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5675000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	952000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3744000	usd
	BRFH	Amounts Included In Measurement Of Lease Liabilities AmountsIncludedInMeasurementOfLeaseLiabilities	20000	usd
	BRFH	Amounts Included In Measurement Of Lease Liabilities AmountsIncludedInMeasurementOfLeaseLiabilities	20000	usd
	BRFH	Value Of Shares Relinquished In Modification Of Stockbased Compensation Awards ValueOfSharesRelinquishedInModificationOfStockbasedCompensationAwards	24000	usd
CY2022Q2	BRFH	Shipping And Handling Costs ShippingAndHandlingCosts	319000	usd
	BRFH	Shipping And Handling Costs ShippingAndHandlingCosts	562000	usd
	BRFH	Shipping And Handling Costs ShippingAndHandlingCosts	768000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	96000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	56000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84D_eus-gaap--UseOfEstimates_zmh6uQHqvMj6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i><span id="xdx_86A_zY6sWH8OG4l9">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities in the balance sheets and revenues and expenses during the years reported. Actual results may differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zVp1N7p0CHL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i><span id="xdx_869_z5Ytob6Rs4Lf">Vendor Concentrations</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company is exposed to supply risk as a result of concentrations in its vendor base resulting from the use of a limited number of contract manufacturers. Purchases from the Company’s significant contract manufacturers as a percentage of all finished goods purchased were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfProductInformationTableTextBlock_zpGwAdJXKjC1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BE_zm6xCYTlHQag" style="display: none">Schedule of Company’s Contract Manufacturers of Finished Goods</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">For the three months ended June 30,</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">For the six months ended June 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Manufacturer A</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerAMember_zdl7dvJENVu2" style="width: 12%; text-align: right" title="Manufacturer percentage">50</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerAMember_zOPk9cnfF9Fk" style="width: 12%; text-align: right" title="Manufacturer percentage">25</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerAMember_zeohg6iLfGI1" style="width: 12%; text-align: right" title="Manufacturer percentage">49</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerAMember_z9xhrM2DUj6i" style="width: 12%; text-align: right" title="Manufacturer percentage">27</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Manufacturer B</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerBMember_zFZFcuShIL0e" style="text-align: right" title="Manufacturer percentage">34</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerBMember_zKjOTjznOT98" style="text-align: right" title="Manufacturer percentage">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerBMember_zyp9zaU0R9Mf" style="text-align: right" title="Manufacturer percentage">41</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerBMember_zq8A4WNwVcPl" style="text-align: right" title="Manufacturer percentage">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Manufacturer C</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerCMember_zY9CBOGozmVa" style="text-align: right" title="Manufacturer percentage">16</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerCMember_zUoPWjus6IYi" style="text-align: right" title="Manufacturer percentage">4</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerCMember_zb6jEkiOaKqh" style="text-align: right" title="Manufacturer percentage">10</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerCMember_znmpTaqn5tU9" style="text-align: right" title="Manufacturer percentage">6</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Manufacturer D</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerDMember_z2pRiHDbtmP9" style="text-align: right" title="Manufacturer percentage">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerDMember_zYS5ceRUjuzd" style="text-align: right" title="Manufacturer percentage">59</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerDMember_zFa1ouIWVVif" style="text-align: right" title="Manufacturer percentage">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerDMember_z0Iqhn1qDBH4" style="text-align: right" title="Manufacturer percentage">59</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Manufacturer E</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerEMember_zLnZy0NIFJHb" style="text-align: right" title="Manufacturer percentage">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerEMember_zh2l3hASZeE5" style="text-align: right" title="Manufacturer percentage">12</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerEMember_z5nuE0AQEN5d" style="text-align: right" title="Manufacturer percentage">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--VendorMember__srt--MajorCustomersAxis__custom--ManufacturerEMember_zuuKOvTwu0Si" style="text-align: right" title="Manufacturer percentage">8</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8AD_zkEAVuVPwTQk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p>
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	211000	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2023Q2	BRFH	Shipping And Handling Costs ShippingAndHandlingCosts	251000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	126000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	801000	usd
CY2022Q4	us-gaap	Assets Assets	5505000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-57972000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2933000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5505000	usd
CY2022Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	96000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	1599000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-716000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	236000	usd
	us-gaap	Operating Expenses OperatingExpenses	3236000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1589000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1589000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	244000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1923000	usd
	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	extended through September 30, 2023
CY2023Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	20000	usd
CY2022Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	20000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	40000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	40000	usd
CY2022	us-gaap	Multiemployer Plan Increase In Employer Contribution Business Combination Percentage MultiemployerPlanIncreaseInEmployerContributionBusinessCombinationPercentage	0.52	pure
CY2023Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	25000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	65000	usd
CY2023Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	945000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	983000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	970000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1048000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3035000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3035000	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2408000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2234000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	627000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	801000	usd
CY2023Q2	us-gaap	Depreciation Depreciation	87000	usd
CY2022Q2	us-gaap	Depreciation Depreciation	90000	usd
	us-gaap	Depreciation Depreciation	174000	usd
	us-gaap	Depreciation Depreciation	212000	usd
CY2023Q2	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	5000	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	10000	usd
	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	10000	usd
	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	10000	usd
	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2023-03-31
CY2021	us-gaap	Multiemployer Plan Increase In Employer Contribution Business Combination Percentage MultiemployerPlanIncreaseInEmployerContributionBusinessCombinationPercentage	0.42	pure
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	8503000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	93000	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	98000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1589000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	7110000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2933000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2933000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	118000	usd
	BRFH	Adjustments To Additional Paid In Capital Cash Settlement Of Equitybased Compensation AdjustmentsToAdditionalPaidInCapitalCashSettlementOfEquitybasedCompensation	-24000	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	83000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1647000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	1463000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	1463000	usd
CY2023Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	684639	shares
CY2023Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.85
CY2023Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	194000	usd
	BRFH	Unrecognized Sharebased Compensation Weighted Average Period UnrecognizedSharebasedCompensationWeightedAveragePeriod	P1Y8M12D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	682939	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.30
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y2M12D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	42045	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.48
	BRFH	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Issued SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Issued	P8Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	108871	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	8.38
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	616113	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.71
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y7M6D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	554902	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.96
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y9M18D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P8Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.844	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.036	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	1.19
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	41923	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	4.92
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	5000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.25
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	4386	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	5.06
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	9931	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	3.33
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	32606	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	4.82
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	24000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2067000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	952000	usd
CY2023Q2	BRFH	Subscription Receivable SubscriptionReceivable	1130000	usd

Files In Submission

Name	View Source	Status
0001493152-23-028441-index-headers.html	Edgar Link	pending
0001493152-23-028441-index.html	Edgar Link	pending
0001493152-23-028441.txt	Edgar Link	pending
0001493152-23-028441-xbrl.zip	Edgar Link	pending
brfh-20230630.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
brfh-20230630_def.xml	Edgar Link	unprocessable
brfh-20230630_cal.xml	Edgar Link	unprocessable
brfh-20230630_pre.xml	Edgar Link	unprocessable
brfh-20230630_lab.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BRFH
BARFRESH FOOD GROUP INC. Stock $brfh

2023 Q3 Form 10-Q Financial Statement

#000149315223028441 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRFH BARFRESH FOOD GROUP INC. Stock $brfh

2023 Q3 Form 10-Q Financial Statement

#000149315223028441 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRFH
BARFRESH FOOD GROUP INC. Stock $brfh